Alan Wookey

Elevating Effective Outcomes with Companion Diagnostics

The successful development and commercialization of personalized medicines often necessitate use of companion diagnostics (CDx).

Now more than ever, drug developers need an experienced global partner to advance CDx development, who understands how to navigate the technical, regulatory and commercialization nuances to enhance the chances of program success.


Additionally, there is a sharpening focus toward smaller populations treated with drugs for orphan indications and rare diseases, umbrella clinical trials where targeted drugs are used for multiple tumor mutations, and basket clinical trials where targeted drugs focus on multiple tumor indications.


For the full article, please click here.